AI Analysis
AI-generated analysis. Always verify with the original filing.
MediWound announced Vericel, its exclusive North America distributor, received a BARDA contract valued at up to $197 million for NexoBrid procurement, manufacturing, and development over ten years.
Key Takeaways
1Vericel awarded 10-year BARDA contract valued at up to $197 million for NexoBrid, effective April 1, 2026.
2Base period of $35 million includes $10 million over next 12 months for initial NexoBrid procurement and VMI establishment.
3Contract covers U.S. Strategic National Stockpile expansion, blast trauma indication development, U.S. manufacturing facility, and room temperature stable formulation.
4NexoBrid is FDA-approved for enzymatic eschar removal in thermal burns, marketed in U.S., EU, Japan, and over 40 countries.
5MediWound has not independently verified Vericel's BARDA contract information.